ABR
0.004
33.3%
BP8
0.001
-50%
SMS
0.049
32.4%
VRXR
0.001
-50%
BPH
0.009
28.6%
MAP
0.045
-28.6%
CAZ
0.02
25%
NES
0.003
-25%
NAG
0.01
25%
OSX
0.004
-20%
FRB
0.185
23.3%
T3D
0.04
-20%
AZI
0.028
21.7%
GHY
0.4
-16.7%
ENN
0.051
21.4%
IPD
0.005
-16.7%
EG1
0.023
21.1%
VTX
0.107
-14.4%
EMT
0.006
20%
AVD
0.15
-14.3%
FEL
0.006
20%
BKT
0.012
-14.3%
YAR
0.006
20%
JAT
0.125
-13.8%
AKM
0.25
19%
DTR
0.112
-13.8%
TZN
0.019
18.8%
VFY
3.29
-13.4%
TG1
0.02
17.6%
SHE
0.013
-13.3%
BNL
0.007
16.7%
CVB
0.041
-12.8%
EPM
0.014
16.7%
MTC
0.17
-12.8%
OSM
0.525
16.7%
STM
0.24
-12.7%
NMT
0.03
15.4%
TOE
0.455
-12.5%
BTM
0.19
15.2%
BMT
0.088
-11.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

PharmAust (ASX:PAA): Extension study begins

Clinical-stage biotechnology company, PharmAust (ASX:PAA), announces that the first patient has been dosed in the Open-Label Extension study at Calvary Health Care Bethlehem, which will investigate the long-term safety, tolerability and efficacy of monepantel in patients with Motor Neurone Disease.

ASX announcement: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02772313-6A1193834